XML 34 R25.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT INFORMATION (Tables)
3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Schedule of segment reporting information
               
    Three Months Ended
March 31,
 
    2025     2024  
Total revenues   $ 41,015     $ 78,671  
Less:                
Cost of revenues (excluding amortization and depreciation)     13,558       9,156  
Research and development expense (excluding share-based compensation expense):                
Clinical trials     79,402       1,238  
Halo Project     298,037       103,477  
Desktop project     23,713       -  
Other research and development     5,136       953  
General and administrative expense (excluding stock based compensation and amortization expense)     622,948       645,719  
Amortization     4,786       2,662  
Stock-based compensation     636,844       161,349  
Professional fees     367,816       227,829  
Interest income, net     (1,103 )     (304 )
Equity in net (income) loss from equity method investees     1,048       (5,783 )
Other income     (22,833 )     (26,468 )
Segment net loss     (1,988,337 )     (1,041,157 )
                 
Reconciliation of net loss                
Adjustments and reconciling items     -       -  
Consolidated net loss   $ (1,988,337 )   $ (1,041,157 )